Microneedles are a type of transdermal drug delivery system in the
form of patches, utilizing ultra-fine needles—approximately
one-third the thickness of human hair—to penetrate the stratum
corneum and deliver drugs through the skin. This innovative
technology offers a more patient-friendly alternative to
injectable formulations.
Through joint research with Daewoong Therapeutics, Daewoong
Pharmaceutical has established its proprietary microneedle
platform technology and is striving to become the global leader in
microneedle-based therapeutics.
Distinguishing Points
Proprietary Platform Technology (Dissolving Microneedles) Through its CLOPAM technology, Daewoong ensures product stability
by fully embedding each microneedle into the mold, preventing
exposure to the external environment. The drug is localized at the
tip of each microneedle to maximize delivery efficiency.
Mass Production TechnologyDaewoong has secured
automated manufacturing capabilities and established facilities to
produce clinical trial materials. A new cGMP-compliant
manufacturing plant is under construction to support future
commercial-scale production.
Open Collaboration Daewoong’s Yongin R&D
Center houses a dedicated GMP facility for microneedle production,
approved through regulatory inspection. This enables end-to-end
collaborative development—from formulation research to clinical
trial materials and drug manufacturing.
Next-Generation Platform Development Daewoong
is advancing next-generation microneedle technologies that address
the limitations of existing systems. These advancements include
increased drug-loading capacity, tunable release profiles, and
detachable microneedle structures to further enhance delivery
efficiency and user convenience.
